TranS1 appoints Reali new CEO

TranS1 Inc. announced that its board of directors has appointed current president and COO, Ken Reali, as chief executive officer of the company. Rick Randall, TranS1 current CEO, will continue to serve as a member of the board in the newly created position of executive chairman of the board. In connection with his appointment as CEO, Reali is also being elected as a member of the board.

"Rick has been instrumental in the development of TranS1 since joining the company in 2002 and we are pleased that he will continue to serve as executive chairman of the board Paul LaViolette, lead director of TranS1, stated in a press release. “Ken has made a significant impact on TranS1 since he joined last year and we are enthusiastic about his leading the company forward."

Reali was initially hired by the TranS1 as president and chief operating officer in January 2010. He has over 20 years of general management, sales and marketing experience with leading medical device and orthopedic companies. He joined the company from Smith & Nephew where he spent 5 years in various senior marketing, sales and product development positions, including most recently as senior vice president and general manager of the biologics and clinical therapies business. Prior to joining Smith & Nephew, Reali held senior marketing, sales and product development positions at Stryker for 7 years and worked as a territory and product manager at Biomet for 8 years.

Commenting on his appointment as CEO, Reali stated, "TranS1 is well positioned to become a significant participant in spinal implants through growth of its AxiaLIF core technology. The company will continue to leverage its strong minimally invasive foundation to develop a business based on technologies that improve outcomes and offer a superior value proposition to current standard of care.